Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Liabilities and Shareholders Equity (2021 - 2025)

PAVmed (PAVM) has 5 years of Liabilities and Shareholders Equity data on record, last reported at $38.1 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity changed N/A year-over-year to $38.1 million; the TTM value through Sep 2025 reached $165.4 million, changed N/A, while the annual FY2024 figure was $30.7 million, 7.42% down from the prior year.
  • Liabilities and Shareholders Equity reached $38.1 million in Q3 2025 per PAVM's latest filing, down from $43.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $87.0 million in Q4 2021 and bottomed at $25.0 million in Q3 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $51.7 million, with a median of $47.4 million recorded in 2021.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 74.06% in 2022, then plummeted 42.94% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $87.0 million in 2021, then crashed by 37.94% to $54.0 million in 2022, then crashed by 38.65% to $33.1 million in 2023, then dropped by 7.42% to $30.7 million in 2024, then grew by 24.17% to $38.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $38.1 million in Q3 2025, $43.9 million in Q2 2025, and $52.8 million in Q1 2025.